期刊文献+

唑来磷酸治疗恶性肿瘤骨转移疼痛的临床疗效观察 被引量:2

下载PDF
导出
摘要 目的观察唑来磷酸治疗恶性肿瘤骨转移疼痛的临床疗效。方法对45例骨转移患者给予唑来磷酸4mg静脉滴注15min,,每4周重复。结果总有效率为80.00%(36/45),其中完全缓解(CR)26.67%(12/45),部分缓解(PR)53.33(24/45)。不良反应为发热、骨关节痛,发生率低。结论唑来磷酸治疗恶性肿瘤骨转移疼痛有良好疗效,不良反应较轻,患者易于耐受,值得临床推广使用。
作者 王燕 苏卫
出处 《中国实用医药》 2011年第7期138-139,共2页 China Practical Medicine
  • 相关文献

参考文献5

二级参考文献23

  • 1秦叔逵,陈映霞,马永泉,李锡麟,刘璐,吴复平.骨膦和^153Sm—EDTMP治疗骨转移癌[J].肿瘤防治研究,1995,22(1):25-27. 被引量:22
  • 2Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase Ⅲ, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol,2003,21 (16) :3150-3157. 被引量:1
  • 3Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate.Clin Ther, 2003,25 ( 11 ) :2669-2708. 被引量:1
  • 4Saad F. Treatment of bone complications in advanced prostate cancer:rationale for bisphosphonate use and results of a phase Ⅲ trial with zoledronic acid. Semin Oncol, 2002,29 (6 Suppl 21 ) : 19-27. 被引量:1
  • 5Bilston LE, Little DG, Smith NC, et al. Zoledronic acid improves the mechanical properties of normal and healing bone. Clin Biomech ( Bristol, Avon), 2002,17(9-10) : 716-718. 被引量:1
  • 6Rosen L, Harland SJ, Oosterlinck W. Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors. Am J Clin Oncol, 2002,25 (6 Suppl 1 ) :S19-24. 被引量:1
  • 7Lipton A, Small E, Saad E, et al. The new bisphosphonate, Zometa(zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest,2002,20( Suppl 2) :45-54. 被引量:1
  • 8Rosen LS,Gordon D,Kaminski M,et at. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 2003,98(8) :1735-1744. 被引量:1
  • 9Weinfurt KP, Castel LD, Li Y,et al. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care, 2004,42 ( 2 ) :164-175. 被引量:1
  • 10Rosen LS,Gordon DH,Dugan W Jr,et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer, 2004 , 100( 1 ) :36-43. 被引量:1

共引文献34

同被引文献8

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部